Antiplatelet drugs 'overused' in majority of patients

More than half stay on dual-antiplatelet therapy longer than recommended: Australian study

More than half of patients pres­cribed dual antiplatelet therapy for coronary artery disease remain on the drugs longer than the recommended 12 months, researchers have found in a Queensland cohort.


They also showed that, despite expectations that the burden of medical therapy would be reduced following stent insertion, this did not occur in practice.

The researchers examined the duration of dual antiplatelet therapy (DAPT) and annual pharmaceutical costs for 740 patients being treated with percutaneous coronary intervention